No Data
Insiders Who Bought in the Last 12 Months Lose an Additional US$130k as Inozyme Pharma, Inc. (NASDAQ:INZY) Drops to US$105m
The recent price decline of 33% in Inozyme Pharma, Inc.'s (NASDAQ:INZY) stock may have disappointed insiders who bought US$450k worth of shares at an average price of US$3.69 in the past 12 months. I
Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 197,900 shares, a decrease of 25.9% from
Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
Globe Newswire 6-Sep-2022 7:30 AMBOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the trea
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 529 companies set new 52-week lows. Noteable 52-Week Lows: NVIDIA (NASDAQ:NVDA) was the biggest company on a market cap basis to set a new 52-week low.Reshape Lifesciences (NASDAQ:RSLS) w
Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 18.8%
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) was the target of a large decrease in short interest during the month of August. As of August 15th, there was short interest totalling 267,000 shares,
Bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.
Bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia
bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.
Needham Sticks to Their Buy Rating for Inozyme Pharma (INZY)
Needham analyst Joseph Stringer reiterated a Buy rating on Inozyme Pharma (INZY – Research Report) today and set a price target of $23.00. The company's shares opened today at $3.41. Stringer covers t
H.C. Wainwright Reaffirms Their Buy Rating on Inozyme Pharma (INZY)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Inozyme Pharma (INZY – Research Report), with a price target of $20.00. The company's shares opened today at $3
Inozyme Pharma GAAP EPS of -$0.38
Inozyme Pharma press release (NASDAQ:INZY): Q2 GAAP EPS of -$0.38. Cash, cash equivalents, and investments were $151.5M as of June 30, 2022. Based on its current plans, the company expects that its
Loading...
